Osteoprotegerin and bone mineral density in patients with chronic obstructive pulmonary disease

Terapevticheskii Arkhiv

Volumn 82, Issue 8, 2010, Pages 10-14

  Kochetkova, E A ^a,b   Nevzorova, V A ^b   Maistrovskaya, Yu V ^b   Massard, G ^a,c  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b PACIFIC STATE MEDICAL UNIVERSITY   (Russian Federation)

^c HÔPITAL CIVIL   (France)

Author keywords

Chronic obstructive pulmonary disease; Osteoporosis; Osteoprotegerin; Tumor necrosis factor

Indexed keywords

OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD; BONE DENSITY; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMUR NECK; HUMAN; MIDDLE AGED; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; RADIOGRAPHY; SPINE;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; CASE-CONTROL STUDIES; FEMUR NECK; HUMANS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957112374     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Biskobing D. M. COPD and osteoporosis. Chest 2002; 121 (2): 609-620.
2. Hofbauer L. C., Khosla S., Dunstan C. R. et al. The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 2000; 15: 2-12.
3. Dougall W. C., Chaisson M. The RANKL/RANK/OPG triad in cancer-induced bone diseases. Cancer Metastas. Rev. 2006; 25: 541-549.
4. Regmi A., Fuson T., Yang X. et al. Suranin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. Bone 2005; 36: 284-297.
5. Sattler A. M., Schoppet M., Schaefer J. R., Hofbauer L. C. Novel aspects on RANK and osteoprotegerin in osteoporosis and vascular disease. Calcif. Tissue Int. 2004; 74: 103-106.
6. Giuliani N., Pedrazzoni M., Negri G. et al. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998; 22: 455-461.
7. Eghbali-Fatourechi G., Khosla S., Sanyal A. et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 2003; 111: 1221-1223.
8. Bucay N., Sarosi I., Dunstan C. R. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12: 1260-1268.
9. Dobnig H., Hofbauer L. C., Viereck V. et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos. Int. 2006; 17: 693-703.
10. Mezquita-Raya P., Higuera M., Garcia D. F. et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos. Int. 2005; 16: 1368-1374.
11. Khosla S., Arrighi H. M., Melton III L. J. et al. Correlates of osteoprotegerin levels in women and men. Osteoporos. Int. 2002; 13: 394-399.
12. Yano K., Tsuda E., Washlda N. et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 1999; 14: 518-527.
13. Szalay F., Hegedus D., Lakatos P. L. et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J. Hepatol. 2003; 38: 395-400.
14. Shoppet M., Sattler A. M., Herzum M. et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin. Endocrinol. 2003; 88: 1024-1028.
15. Rogers A., Saleh G., Hannon R. A. et al. Circulating estradiol and osteoprotegerin as determinant of bone turnover and bone density in postmenopausal women. J. Clin. Endocrinol. 2002; 87: 4470-4475.
16. Monegal A., Navasa M., Peris P. et al. Serum osteoprotegerin and its ligand in cirrhotic patients referred for osteoporotic liver transplantation: relationship with metabolic bone disease. Liver Int. 2007; 5: 492-497.
17. Warren S., Browner W. S., Lui L. Y., Steven R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. 2001; 86: 631-637.
18. Pennisi P., Signorelli S. S., Ricobene S. et al. Low bone density and abnormalin patients with atherosclerosis of peripheral vessels. Osteoporos. Int. 2004; 15: 389-395.
19. Baud'huin M., Lamoureux F., Duplomb L. et al. RANKL, RANK, osteoprotegerine: key partners of osteoimmunology and vascular diseases. Cell Mol. Life Sci. 2007; 64: 2334-2350.
20. Incalzi R. A., Caradonna P., Raniert P. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir. Med. 2000; 94: 1079-1084.
21. Bolton C. E., Ionescu A. A., Shiels K. M. et al. Associated loss fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170 (12): 1286-1293.
22. Serelis J., Kontogianni M. D., Katsiougiannis S. et al. Effect of anti-TNF treatment on body composition and serum adiponectin level of women with rheumatoid arthritis. Clin. Rheumatol. 2008; 27: 795-797.
23. Olesen P., Ledet T., Rasmussen L. M. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α. Diabetologia 2005; 48: 561-568.